This leads to relatively smooth (though not flawless) northbound trajectories and strong returns for most stocks over a ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Gulf South Angels, a New Orleans-based investment network, is investing in non-opioid pain drug startup South Rampart Pharma, ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

Re “The cops were Black. But acquitting the officers involved with Tyre Nichols death was racial” (column, May 11): LAPD ...

And that statement also applies to another new launch -- non-opioid painkiller Journavx. Vertex expects to transition Trikafta patients to Alyftrek and build a multibillion-dollar pain management ...

That boost came from increased patient demand and the launch of new products, including ALYFTREK for cystic fibrosis and JOURNAVX for pain management. International sales, however, didn’t get the memo ...

It’s the same system Vertex Pharmaceuticals used in the studies that ultimately led to the approval of Journavx, a closely watched, non-opioid pain reliever. Viatris, like Vertex, also set up arms in ...

Stifel kept a Hold rating with a $194 target, focusing on the promising early prescription data for Journavx and the critical Phase 3 program for suzetrigine, a treatment for diabetic peripheral ...